lasofoxifene has been researched along with Thromboembolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andreu, JL; Silva-Fernández, L | 1 |
| Calaf Alsina, J; Coronado Martín, PJ | 1 |
1 review(s) available for lasofoxifene and Thromboembolism
| Article | Year |
|---|---|
[Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hot Flashes; Humans; Indoles; Menopause; Multicenter Studies as Topic; Organ Specificity; Osteoporosis, Postmenopausal; Piperidines; Pyrrolidines; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tetrahydronaphthalenes; Thiophenes; Thromboembolism | 2013 |
1 other study(ies) available for lasofoxifene and Thromboembolism
| Article | Year |
|---|---|
Lasofoxifene for postmenopausal women with osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Risk; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thromboembolism | 2010 |